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Aims Although the presence of the electrocardiographic (ECG) strain pattern has been associated with an increased risk of
developing heart failure (HF), the relationship of regression vs. persistence vs. development of new ECG strain to
subsequent HF is unclear.
Methods
and results
Electrocardiographic strain was evaluated at baseline and at year-1 in 7265 hypertensive patients without HF treated
with atenolol- or losartan-based regimens. During 3.9+0.7 years of follow-up after the year-1 ECG, 154 patients
(2.1%) were hospitalized for HF. Five-year HF incidence was lowest in patients with no ECG strain (1.6%), intermedi-
ate in patients with regression of strain (5.4%), and highest in patients with persistent (7.1%) or new strain (7.0%;
P , 0.0001 across groups). In the Cox multivariable analyses adjusting for the known predictive value of in-treatment
ECG left ventricular hypertrophy by the Cornell product and Sokolow–Lyon voltage, in-treatment QRS duration,
systolic and diastolic pressure, incident myocardial infarction and atrial fibrillation, randomized treatment and
other risk factors for HF, regression of strain [hazards ratio (HR) 2.4, 95% confidence interval (CI) 1.2–5.0], persist-
ence of strain (HR 1.9, 95% CI 1.2–3.2), and development of new ECG strain (HR 2.3, 95% CI 1.2–4.4) were all
independently associated with an increased risk of new HF compared with the absence of ECG strain on both base-
line and year-1 ECGs.
Conclusion The development of new ECG strain or persistence of ECG strain between baseline and year-1 is associated with
an increased risk of HF. The regression of ECG strain between baseline and year-1 does not convey a decreased
risk of HF.
Clinical trials registration: http://clinicaltrials.gov/ct/show/NCT00338260.
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Introduction
The classic strain pattern of lateral ST depression and T-wave
inversion on the electrocardiogram (ECG) is a well-recognized
marker of the presence and severity of anatomical left ventricular
hypertrophy (LVH).1– 7 Electrocardiographic strain is associated
with depressed LV function5 and improves ECG detection of struc-
tural hypertrophy when incorporated into scores that include stan-
dard voltage criteria.2,4 Electrocardiographic strain has been
associated with adverse prognosis in a variety of populations,8– 14
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including hypertensive patients,8,9,12–14 and has often been the
primary marker of untoward outcomes when ECG LVH criteria
have been utilized for risk stratification.8,12,13 Indeed, strain on
the baseline ECG was an independent predictor of cardiovascular
(CV) morbidity and mortality9 and new-onset heart failure (HF)14
among hypertensive patients with ECG LVH in the LIFE study.
The serial assessment of ECG voltage and voltage–duration
product criteria for LVH has demonstrated that the regression of
ECG LVH appears to confer a decreased risk of CV mortality and
morbidity, including the development of new HF.11– 13,15–18
Among LIFE study patients,18 a greater than median decrease in
the Cornell product LVH was associated with a 36% lower adjusted
risk of HF hospitalization, independent of treatment modality, blood
pressure lowering, and other HF risk factors. The persistence or
development of new ECG strain were strongly associated with an
increased risk of CV morbidity and mortality in the LIFE study19
and with an increased risk of a composite CV endpoint that included
new-onset HF in patients with essential hypertension.12 However,
whether changes in the ECG strain pattern provide additional prog-
nostic information for HF onset beyond that provided by changes in
ECG LVH18 and QRS duration20 in the LIFE study population has not
been examined. Therefore, the present study examined the relation-
ship of the strain pattern on the baseline and year-1 ECGs in the LIFE
study to the risk of HF hospitalization, independent of other HF risk
factors, treatment effects, blood pressure reduction, and of the
known effects of in-treatment QRS duration20 and regression of
ECG LVH on HF incidence.18
Methods
Subjects
The LIFE study21,22 enrolled hypertensive patients with ECG LVH by
the Cornell product23 and/or Sokolow–Lyon voltage criteria1 on a
screening ECG in a prospective, double-blind study large enough
(n ¼ 9193) to demonstrate an appreciable reduction in mortality and
morbid events with the use of losartan as opposed to atenolol.21 Eli-
gible patients were men and women aged 55–80 years with previously
untreated or treated essential hypertension with mean blood pressure
in the range 160–200/95–115 mmHg after 1 and 2 weeks on placebo.
A total of 7265 patients with no history of HF by patient self-report
prior to enrolment or during the first year of treatment in LIFE had
baseline and year-1 ECGs on which the strain pattern could be deter-
mined (3906 women and 3359 men, mean age 67+7 years).
Electrocardiography
Hard-copy ECGs were interpreted at a core laboratory by experi-
enced readers blinded to clinical information as previously reported
in detail.5,9 QRS duration was measured to the nearest 4 ms in all 12
leads and R-wave amplitudes in leads aVL, V5, and V6 and S-wave
amplitudes in leads V1 and V3 were measured to the nearest
0.5 mm (0.05 mV).5,9,20 The product of QRS duration times the
Cornell voltage combination [RaVL + SV3, with 6 mm (0.6 mV)
added in women] .2440 mm ms5,22 or the Sokolow–Lyon voltage
(SV1 + RV5/6) .38 mm1,22 was used to identify ECG LVH.
The determination of the presence or absence of ECG strain as a
dichotomous variable was visually assessed on baseline and year-1
ECGs at Helsinki University Central Hospital as described pre-
viously.5,9 Repolarization abnormalities in leads V5 and/or V6 were
considered consistent with the presence of typical strain when there
was a down-sloping convex ST-segment with an inverted asymmetrical
T-wave with polarity opposite to the main QRS deflection.5,9
Endpoint determination
Hospitalization for HF was a pre-specified secondary endpoint in the
LIFE study.18,22 The diagnosis of HF was based on clinical and diagnos-
tic findings modified from Framingham criteria24 that are outlined in
Table 1. Each case was reviewed and verified by the Endpoint
Committee, which was blinded to study ECG strain and LVH results
when classifying possible morbid events.21,22
Statistical methods
Data management and analysis were performed with SPSS version 12.0
software. Data are presented as mean+ SD for continuous variables
and proportions for categorical variables. Patients were classified
into four groups according to the presence or absence of strain at
baseline and year-1 as follows: no strain on either ECG (absence of
strain); strain at baseline but not at year-1 (regression of strain);
strain on both ECGs (persistence of strain); or no strain at baseline
and strain at year-1 (development of new strain). Differences in preva-
lences between groups were compared using x2 analyses and mean
values of continuous variables were compared using one-way
ANOVA, with P-values given for the statistical significance of the
linear trend across groups.
Event rates were calculated and plotted according to the Kaplan–
Meier product limit method and statistical significance tested for the
linear trend across groups using the log-rank statistic. The relation of
strain at baseline and year-1 to the risk of developing new HF was
assessed using Cox’s proportional hazards models. Partial residuals
were plotted against survival times and visually examined to check
the proportional hazards assumption. To test the independence of
serial assessment of ECG strain for incident HF, the presence or
absence of ECG strain at baseline and year-1 was entered into a multi-
variable Cox model that also included as covariates age, gender, treat-
ment group, race, diabetes, history of ischaemic heart disease,
myocardial infarction, stroke, peripheral vascular disease, atrial fibrilla-
tion and smoking, baseline urinary albumin/creatinine ratio, total and
HDL cholesterol, glucose, creatinine, uric acid, and body mass index
as standard covariates, and baseline and in-treatment values of systolic
and diastolic pressure, QRS duration, the Cornell product, the
Sokolow–Lyon voltage, and incident myocardial infarction and atrial
fibrillation as time-varying covariates.
Analyses were repeated stratifying the population by sex, age, race,
treatment group, history of ischaemic heart disease, prevalent diabetes,
and by the presence or absence of LVH by the Cornell product and
Sokolow–Lyon voltage on the baseline ECG. The interaction
between the presence or absence of strain at baseline and year-1
and these variables was formally tested by adding cross-product
terms of strain and these variables into the models of the total popu-
lation. For all tests, a two-tailed P-value of ,0.05 was required for stat-
istical significance.
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Results
Electrocardiographic strain was absent on both baseline and year-1
ECGs in 6236 patients (85.8%), regressed from baseline to year-1
in 236 (3.2%), persisted on both ECGs in 517 (7.1%), and was
absent at baseline but developed by year-1 in 276 patients
(3.8%). Clinical and demographic characteristics of patients in
relation to the presence or absence of ECG strain at baseline
and year-1 are shown in Table 2. Patients without strain on
either ECG were younger, more likely to be female, less likely to
be black, current smokers or have diabetes, a history of ischaemic
heart disease, myocardial infarction, stroke, peripheral vascular
disease or atrial fibrillation, had higher total and HDL cholesterol
levels, less albuminuria, and lower serum glucose, creatinine, and
uric acid levels.
Blood pressure and ECG LVH measurements at baseline and
changes in these measurements between baseline and last
in-study determination in relation to the presence or absence of
ECG strain on baseline and year-1 ECGs are shown in Table 3.
The absence of strain on both ECGs was associated with lower
baseline systolic pressures, the Cornell product and Sokolow–
Lyon voltage, and with smaller reductions in systolic and diastolic
pressure. The regression of strain between baseline and year-1
was associated with the greatest reductions in the Cornell
product and Sokolow–Lyon voltage, whereas the development
of new strain was associated with the smallest reductions in the
Cornell product LVH during the course of the study.
During 3.9+ 0.7 years of follow-up after the year-1 ECG, 154
patients (2.1%) had a new HF hospitalization. The relationship of
serial evaluation of ECG strain at baseline and year-1 to HF hospital-
ization is shown in Table 4 and Figure 1. Five-year incidence of
hospitalization for HF was lowest in patients with no ECG strain
(1.6%), intermediate in patients with regression of strain (5.4%),
and highest in patients with persistent (7.1%) or new strain (7.0%;
P , 0.0001 across groups). Strain on the baseline and/or year-1
ECG was associated with 39.6% (61 of 154) of new cases of HF,
although strain was present in only 14.2% of the study population.
In univariate Cox’s analyses, the persistence of strain or develop-
ment of a new ECG strain pattern was associated with the highest
risk of developing HF, with 4.4- to 4.5-fold increased risks compared
with the absence of strain on both ECGs, whereas patients with
regression of strain between baseline and year-1 had a greater
than three-fold increased risk of HF hospitalization.
Because patients who developed strain differed significantly
from those who did not with respect to demographic and clinical
variables which could affect outcome (Tables 1 and 2), the inde-
pendent relation of new HF to the presence or absence of strain
at baseline and year-1 was examined after adjusting for the possible
effects of treatment, age, gender, race, prevalent diabetes, history
of ischaemic heart disease, myocardial infarction, stroke, peripheral
vascular disease, atrial fibrillation and smoking, baseline urinary
albumin/creatinine ratio, total and HDL cholesterol, glucose, crea-
tinine, uric acid, and body mass index and for the possible effects of
baseline and in-treatment systolic and diastolic blood pressure,
QRS duration, the Cornell product and Sokolow–Lyon voltage,
and incident myocardial infarction and atrial fibrillation treated as
time-dependent covariates (Table 4). After adjusting for these
factors, the development of new ECG strain, persistence of
strain, and regression of ECG strain were each associated with
an approximately two-fold increased risk of HF hospitalization.
Importantly, in-treatment ECG LVH by the Cornell product and
Sokolow–Lyon voltage, treated as time-varying covariates,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Criteria for diagnosis of heart failure on hospitalizationa
Major criteria Minor criteria
Clinical findings Clinical findings
Paroxysmal nocturnal dyspnoea Night cough
Jugular venous distension Dyspnoea on ordinary exertion
Pulmonary rales Bilateral ankle oedema
Ventricular S3 gallop Hepatomegaly
Hepatojugular reflux
Diuresis of 10 pounds or 5 kg in response to diuretic
treatment with clinical improvement in congestive symptoms
Diagnostic findings Diagnostic findings
Chest X-ray Chest X-ray
Acute pulmonary oedema on chest X-ray Pleural effusion or pulmonary vascular engorgement or redistribution
Haemodynamic Haemodynamic
Pulmonary capillary wedge pressure ≥20 mmHg Pulmonary capillary wedge pressure of 16–19 mmHg
Left ventricular ejection fraction ≤35% Left ventricular ejection fraction of 36–44%
Cardiac index ,2.0 L/min Cardiac index of 2.0–2.4 L/min
Evidence of severe valvular heart disease Evidence of moderate valvular heart disease
Autopsy
Pulmonary oedema, visceral congestion or cardiomegaly
aA definite diagnosis of heart failure required a minimum of: one major clinical plus one major diagnostic finding; or one major clinical plus two minor diagnostic findings; or one
minor clinical plus two major or minor diagnostic criteria. Minor criteria were accepted only if they could not be attributed to another disease process.24
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remained significant predictors of HF hospitalization in this multi-
variable Cox model (data not shown).
The predictive value of the presence or absence of ECG strain at
baseline and year-1 for the development of new HF in relevant
subsets of the population is examined in Table 5. The association
between baseline and year-1 ECG strain and HF hospitalization
was similar in men and women, blacks and other ethnicities, in
both treatment arms of the study, in patients above and below
65 years of age, among patients with and without a history of
ischaemic heart disease and with or without prevalent diabetes,
and among patients with and without LVH on their baseline
ECG by either the Cornell product or the Sokolow–Lyon
voltage criteria, with non-significant interaction terms for these
variables.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Baseline and change from baseline to last in-study measurement of blood pressure and electrocardiographic left
ventricular hypertrophy in relation to the presence of electrocardiographic strain at baseline and year-1
Variables Strain2/strain2
(n 5 6236), no
strain
Strain1/strain2
(n 5 236), regression
of strain
Strain1/strain1
(n 5 517), persistent
strain
Strain2/strain1





Systolic BP (mmHg) 173.9+14.4 176.4+14.2 176.9+14.8 177.4+13.7 ,0.001
Diastolic BP (mmHg) 98.2+8.5 97.6+9.8 97.4+9.8 97.8+9.6 0.222
Cornell’s product (mm ms) 2618+717 2932+961 2923+913 2853+925 ,0.001
Sokolow–Lyon voltage (mm) 28.9+9.9 35.0+10.5 37.8+11.1 33.6+10.9 ,0.001
Change from baseline to last measurement
Systolic BP (mmHg) 229.8+19.3 232.0+20.0 232.1+18.9 232.7+21.2 0.010
Diastolic BP (mmHg) 217.3+10.0 218.0+10.7 218.7+10.4 218.0+11.4 0.017
Cornell’s product (mm ms) 2208+692 2372+857 2201+929 2119+936 0.001
Sokolow–Lyon voltage (mm) 23.8+6.8 27.7+8.9 24.8+9.9 23.8+9.2 ,0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Demographic and clinical characteristics in relation to the presence of electrocardiographic strain at baseline
and year-1
Variables Strain2/strain2









(n 5 276), new
strain
P-valuea
Age (years) 66.3+7.0 66.8+7.1 67.9+6.8 69.1+6.8 ,0.001
Sex (% female) 55.8 38.1 38.3 49.3 ,0.001
Race (% Black) 4.2 9.3 15.3 8.0 ,0.001
Diabetes (%) 11.5 14.4 18.0 17.0 ,0.001
History of IHD (%) 11.3 26.3 30.9 22.8 ,0.001
History of MI (%) 3.9 8.9 13.5 10.4 ,0.001
History of stroke (%) 3.5 4.2 7.5 6.5 ,0.001
History of PVD (%) 4.8 7.6 8.9 8.0 ,0.001
History of AFib (%) 2.5 5.1 5.4 10.1 ,0.001
Current smoker (%) 15.0 20.8 17.6 26.1 ,0.001
Treatment with losartan (%) 50.6 53.8 48.2 41.7 0.014
Body mass index (kg/m2) 28.1+4.7 27.7+4.4 27.7+4.9 27.6+5.0 0.134
Total cholesterol (mM) 6.06+1.10 5.89+1.18 5.91+1.16 5.98+1.14 0.003
HDL cholesterol (mM) 1.52+0.44 1.41+0.37 1.40+0.40 1.41+0.40 ,0.001
UACR (mg/mM) 5.6+28.2 8.0+18.8 13.1+42.2 12.9+32.0 ,0.001
Glucose (mM) 5.92+2.00 6.26+2.34 6.36+2.89 6.30+2.50 ,0.001
Creatinine (mM) 84.6+18.3 94.3+24.9 95.4+21.9 91.7+20.2 ,0.001
Uric acid (mg/mM) 325+77 350+77 347+76 338+76 ,0.001
AFib, atrial fibrillation; IHD, ischaemic heart disease; MI, myocardial infarction; PVD, peripheral vascular disease; UACR, urine albumin/creatinine ratio.
aDifferences in prevalences between groups were compared using x2 analyses and mean values of continuous variables were compared using ANOVA for linear trend.
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Discussion
This study demonstrates that the development of new ECG strain
or persistence of ECG strain between baseline and year-1 during
the LIFE study was associated with an increased risk of hospitaliz-
ation for new HF and that the regression of ECG strain between
baseline and year-1 does not convey a decreased risk of developing
HF. The increased risk of HF associated with ECG strain at baseline
and/or year-1 was independent of the previously demonstrated
predictive values of in-treatment ECG LVH18 and QRS duration20
for new HF, of the baseline and in-treatment severity of
hypertension, and persisted after adjusting for randomized treat-
ment and the higher prevalence of other CV disorders and HF
risk factors associated with ECG strain. These findings highlight
the adverse prognostic value of ECG strain, even if not persistent
between ECG evaluations, for new HF in hypertensive patients in
the setting of substantial decreases in both systolic and diastolic
pressure and suggest that more aggressive therapy may be war-
ranted in hypertensive patients who have ECG strain to reduce
the risk of developing new HF.
Electrocardiographic strain and the
prediction of heart failure
Although the relationship of CV risk to the ECG strain pattern on a
single ECG has been demonstrated in population-based studies
and patients with hypertension,8 –13 the relationship of ECG
strain to new-onset HF has been less well characterized.8,13,14 Ver-
decchia et al.8 found strain on a baseline ECG to be associated with
a greater than two-fold increased risk of a composite CV endpoint
that included a small number of hospitalizations for new HF in
1717 hypertensive subjects, but did not separately examine the
predictive value of ECG strain for new HF. Similarly, among over
28 000 patients enrolled in either ONTARGET or TRANS-
CEND,13 baseline strain alone was associated with a 1.7-fold
increased risk and strain in combination with ECG LVH by modi-
fied Cornell’s voltage criteria with a 2.2-fold increased risk of a
composite CV endpoint which included the development of new
HF. However, the predictive value of ECG strain for new HF
alone was not reported.13 In contrast, previous evaluation in the
LIFE study14 revealed that strain on a baseline ECG was an inde-
pendent predictor of new-onset HF and was associated with a
70% increased risk of developing HF. However, these studies did
not examine the relationship of ECG strain over time to CV out-
comes or the development of new HF.
The relationship of the presence or absence of ECG strain over
time to CV outcomes has not been extensively evaluated11,12,19
and no previous study has examined the predictive value of
serial evaluation of ECG strain for new HF. In contrast, the
present study demonstrates that the development of new strain,
persistence of strain, and regression of ECG strain between
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Five-year heart failure incidence, univariate and multivariable Cox’s regression analyses to assess the relation of
new heart failure to electrocardiographic strain at baseline and year-1
Event Strain2/strain2
(n 5 6236), no
strain
Strain1/strain2
(n 5 236), regression of
strain
Strain1/strain1
(n 5 517), persistent
strain
Strain2/strain1




5-year event rates (%)
Heart failure incidence (%) 1.6 5.4 7.1 7.0 ,0.0001
Hazard ratios (95% confidence intervals)
Univariate Cox’s model 1 3.2 (1.7–6.1) 4.5 (3.1–6.7) 4.4 (2.6–7.4) ,0.001
Multivariate Cox’s modela 1 2.4 (1.2–5.0) 1.9 (1.2–3.2) 2.3 (1.2–4.4) ,0.001
aAdjusted for possible effects of treatment with losartan vs. atenolol, age, gender, race, prevalent diabetes, history of ischaemic heart disease, myocardial infarction, stroke,
peripheral vascular disease, atrial fibrillation or smoking, baseline albumin/creatinine ratio, total and HDL cholesterol, glucose, creatinine, uric acid, and body mass index entered as
standard covariates, and baseline and in-treatment systolic and diastolic blood pressure, QRS duration, the Sokolow–Lyon voltage, the Cornell voltage–duration product, and
incident myocardial infarction and atrial fibrillation entered as time-varying covariates.
Figure 1 Kaplan–Meier curves comparing new-onset heart
failure rates between patients according to the presence or
absence of electrocardiographic strain on their baseline and
year-1 electrocardiograms. (n ¼ number of patients; strain2/
strain2 represents the absence of strain on baseline and year-1
electrocardiogram; strain+/strain2 represents the presence of
strain on baseline electrocardiogram and the absence of strain
on year-1 electrocardiogram, regression of strain; strain+/
strain+ represents the presence of strain on baseline and
year-1 electrocardiogram, persistence of strain; strain2/strain+
represents the absence of strain on baseline electrocardiogram
and the presence of strain on year-1 electrocardiogram, develop-
ment of new strain).
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baseline and year-1 were associated with an increased risk of new
HF, independent of the possible impact of standard CV risk factors,
randomized treatment assignment, baseline and in-treatment dias-
tolic and systolic blood pressure, and of the previously demon-
strated prognostic value of in-treatment ECG LVH and QRS
duration for new HF in this population.18,20 In addition, the associ-
ation of baseline and year-1 strain and new HF was similar in all rel-
evant subsets of the population. Furthermore, similar to the
predictive value of baseline and year-1 strain for CV morbidity
and mortality in the LIFE study population,19 the regression of
ECG LVH by the Cornell product and Sokolow–Lyon voltage
retained the predictive value for new HF outcomes in the
current study when the serial assessment of ECG strain is taken
into account, emphasizing the need for the serial assessment of
both standard ECG LVH criteria and lateral repolarization abnorm-
alities to accurately assess changing risk over time in the hyperten-
sive population.
Although the precise mechanisms linking the development of
ECG strain to the development of HF are not known, the strong
association of strain with abnormalities of CV structure and func-
tion may in part explain the adverse prognosis associated with
strain. In the present study, patients with new or persistent
strain were older, had higher prevalences of diabetes, history of
various forms of heart and vascular disease, and evidence of
greater end-organ damage as manifested by albuminuria. In
addition, patients who developed new ECG strain had the least
regression of ECG LVH by the Cornell product criteria, suggesting
less improvement in LVH despite similar reductions in blood
pressure in this group. However, new ECG strain remained predic-
tive of outcomes in the current study after adjusting for the poss-
ible impact of these factors. In the echocardiographic substudy of
LIFE5 and a cross-sectional study of 440 patients with resistant
hypertension,7 baseline ECG strain was strongly related to the
presence of coronary heart disease, increased LV mass, and echo-
cardiographic LVH that was more likely to be concentric, factors
that predispose to increased CV risk. Further analysis of baseline
LV mass and function in relation to both baseline and year-1
ECG strain in the echocardiographic substudy of LIFE5 demon-
strated that baseline LV mass index was highest and LV midwall
shortening was lowest and most likely to be abnormal in patients
with persistent or new ECG strain and that baseline LV mass
was also elevated in patients with regression of strain between
baseline and year-1. The absence of a significant association
between baseline ECG strain and echocardiographic measures of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Cox’s analyses to assess the predictive value of electrocardiographic strain at baseline and year-1 for new-onset


















Male (n ¼ 3359) 77 1 1.7 (0.6–4.8) 4.4 (2.6–7.4) 3.8 (1.8–8.0) 0.286
Female (n ¼ 3906) 77 1 6.0 (2.7–13.2) 4.5 (2.4–8.4) 5.0 (2.4–10.1)
Race
White or other (n ¼ 6877) 136 1 2.3 (1.1–5.1) 4.7 (3.1–7.2) 4.3 (2.5–7.5) 0.167
Black (n ¼ 388) 18 1 6.8 (2.0–23.3) 2.4 (0.7–7.4) 3.5 (0.7–16.7)
Treatment
Atenolol (n ¼ 3617) 78 1 1.9 (0.6–6.1) 4.6 (2.6–8.0) 5.9 (3.2–11.0) 0.261
Losartan (n ¼ 3648) 76 1 4.4 (2.1–9.4) 4.5 (2.6–8.0) 2.4 (0.9–6.7)
Age (years)
Less than 65 (n ¼ 2902) 37 1 2.2 (0.5–9.5) 6.2 (2.9–13.4) 5.0 (1.5–16.7) 0.626
65 or greater (n ¼ 4363) 117 1 3.7 (1.8–7.4) 3.9 (2.4–6.2) 3.8 (2.1–6.7)
History of IHD
No (n ¼ 6277) 100 1 4.0 (1.9–8.4) 3.5 (2.0–6.2) 5.5 (3.1–10.1) 0.104
Yes (n ¼ 988) 54 1 1.2 (0.4–4.1) 3.2 (1.8–5.7) 1.6 (0.6–4.7)
Diabetes
No (n ¼ 6373) 110 1 3.6 (1.7–7.5) 5.9 (3.7–9.2) 4.8 (2.6–9.0) 0.082
Yes (n ¼ 892) 44 1 2.2 (0.7–7.1) 1.6 (0.7–3.9) 2.7 (1.1–7.1)
CP LVH
No (n ¼ 2583) 41 1 2.4 (0.6–10.2) 4.2 (1.7–10.1) 6.5 (2.7–15.9) 0.682
Yes (n ¼ 4682) 113 1 3.4 (1.7–6.8) 4.4 (2.8–6.9) 3.6 (1.9–6.8)
SL LVH
No (n ¼ 5712) 103 1 3.9 (1.8–8.5) 5.5 (3.3–9.3) 5.0 (2.7–9.3) 0.233
Yes (n ¼ 1553) 51 1 1.9 (0.7–5.3) 2.5 (1.3–4.8) 2.8 (1.1–7.3)
CP, Cornell product; HF, heart failure; IHD, ischaemic heart disease; SL, Sokolow–Lyon voltage.
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diastolic dysfunction25 further suggests that the predictive value of
ECG strain for new HF may be mediated via abnormalities of LV
systolic function. However, the small number of incident HF
cases among the 770 patients in the LIFE echocardiography sub-
study who were included in the present study (n ¼ 12) precludes
meaningful analysis of the relationship of LV systolic or diastolic
function to new-onset HF in this population. This problem and
the strong association of hypertension with impaired LV diastolic
function in a recent population-based study26 suggests that
further evaluation of the relationship of ECG strain to the develop-
ment of LV systolic and diastolic dysfunction and HF will be necess-
ary. In addition to the possible relation of ECG strain to coronary
heart disease and LV mass,5,7 ST depression and T-wave inversion
may reflect true subendocardial ischaemia in the absence of coron-
ary disease, because of hypertrophy-induced compensatory
increases in coronary artery diameter that are inadequate for the
magnitude of increased LV mass and wall thickness.27– 29 This
concept is supported by the association of ECG strain with
increased wall stress–mass–heart rate product among hyperten-
sive patients with ECG LVH but no evidence of coronary disease
in the LIFE study,5 providing evidence of a demand-side predisposi-
tion to myocardial ischaemia in these patients.
Study limitations and perspectives
The independent relation of the presence of ECG strain at baseline
and/or year-1 to increased risk of HF in LIFE despite aggressive
blood pressure reduction suggests that the presence or develop-
ment of new strain on the ECG may be used to identify hyperten-
sive patients with ECG LVH who require more aggressive
antihypertensive therapy aimed at further reducing HF risk in
these patients. However, there are several potential limitations
of our study that warrant review. First, the use of hospitalization
for HF to define incident HF most certainly underestimates the
true incidence of HF, potentially reducing precision of the esti-
mates of the relationship of ECG strain changes to HF incidence.
Secondly, the relatively small number of cases of HF associated
with strain potentially limits the ability to differentiate the impact
between old and new strain on HF incidence. Thirdly, although it
would be of interest to examine changes in LV structure and func-
tion according to changes in ECG strain and the development of
new HF, the small number of incident HF cases in the echocardio-
graphic substudy of LIFE precludes meaningful analyses along these
lines. Fourthly, the inferences that may be drawn from the present
study are potentially limited by the lack of ECG strain data on
ECGs obtained after year-1 and by the absence of quantitative
data assessing the degree of ST depression in this population. Pre-
vious observations that the magnitude of ST depression in the
lateral leads is strongly related to the presence and severity of
LVH6 and that measured ST depression and echocardiographic
LV mass provide complimentary prognostic information30 suggest
that the serial assessment of the magnitude of lateral repolarization
abnormality may provide additional prognostic benefit in hyperten-
sive patients. Further study will be necessary to address this impor-
tant question. Finally, given that a clinical diagnosis of HF in the
community is commonly based, at least in part, on findings on
the ECG,31 the current findings suggest that the serial evaluation
of the presence of strain on the ECG may increase the utility of
the ECG in detecting new-onset HF.
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Nieminen MS, Dahlöf B, Devereux RB. Electrocardiographic strain pattern and
left ventricular diastolic function in hypertensive patients with left ventricular
hypertrophy: the LIFE Study. J Hypertension 2006;24:2079–2084.
26. Russo C, Jin Z, Homma S, Rundek T, Elkind MSV, Sacco RL, Di Tullio MR. Effect of
diabetes and hypertension on left ventricular diastolic function in a high-risk popu-
lation without evidence of heart disease. Eur J Heart Fail 2010;12:454–461.
27. Rembert JC, Kleinman LH, Fedor JM, Wechsler AS, Greenfield JC Jr. Myocardial
blood flow distribution in concentric left ventricular hypertrophy. J Clin Invest
1978;62:379–386.
28. O’Keefe JH, Owen RM, Bove AA. Influence of left ventricular mass on coronary
artery cross-sectional area. Am J Cardiol 1987;59:1395–1397.
29. Anderson HV, Stokes MJ, Leon M, Abu-Halawa SA, Stuart Y, Kirkeeide RL. Cor-
onary flow velocity in related to lumen area and regional left ventricular mass.
Circulation 2000;102:48–54.
30. Okin PM, Roman MJ, Lee ET, Galloway JM, Howard BV, Devereux RB. Combined
echocardiographic left ventricular hypertrophy and electrocardiographic ST
depression improve prediction of mortality in American Indians: The Strong
Heart Study. Hypertension 2004;43:769–774.
31. Dahlstrom U, Hakansson J, Swedberg K, Waldenstrom A. Adequacy of diagnosis
and treatment of chronic heart failure in primary health care in Sweden. Eur J
Heart Fail 2009;11:92–98.
ECG strain and new heart failure 391
